Selective protein degradation platforms have afforded new development opportunities for
therapeutics and tools for biological inquiry. The first lysosome-targeting chimeras (LYTACs) …

Currently approved immune checkpoint inhibitor therapies targeting the PD-1 and CTLA-4
receptor pathways are powerful treatment options for certain cancers; however, most patients …

Targeted protein degradation is an emerging strategy for the elimination of classically
undruggable proteins. Here, to expand the landscape of targetable substrates, we designed …

Tetraspanins are an evolutionary conserved family of proteins involved in multiple aspects
of cell physiology, including proliferation, migration and invasion, protein trafficking, and …

Background Antibody drug conjugates (ADCs) targeting the epidermal growth factor
receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic …

V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA) is an immune checkpoint
that maintains peripheral T cell quiescence and inhibits anti-tumor immune responses. …

Promoting immune activation within the tumor microenvironment (TME) is a promising
therapeutic strategy to reverse tumor immunosuppression and elicit anti-tumor immunity. To …

Spontaneous tumors that arise in genetically engineered mice recapitulate the natural tumor
microenvironment and tumor-immune coevolution observed in human cancers, providing a …

Selective protein degradation platforms have afforded new development opportunities for
therapeutics and tools for biological inquiry. The first lysosome targeting chimeras (LYTACs) …

Currently approved immune checkpoint inhibitor (ICI) therapies targeting the PD-1 and
CTLA-4 receptor pathways are powerful treatment options for certain cancers; however, the …